ALLO
Income statement / Annual
Last year (2023), Allogene Therapeutics, Inc.'s total revenue was $95,000.00,
a decrease of 60.91% from the previous year.
In 2023, Allogene Therapeutics, Inc.'s net income was -$327.27 M.
See Allogene Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$95,000.00 |
$243,000.00 |
$38.49 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$242.91 M
|
$16.73 M
|
$13.07 M
|
$11.54 M
|
$5.03 M
|
$1.50 M
|
$0.00
|
| Gross Profit |
-$242.82 M
|
-$16.49 M
|
$25.42 M
|
-$11.54 M
|
-$5.03 M
|
-$1.50 M
|
$0.00
|
| Gross Profit Ratio |
-2555.99
|
-67.84
|
0.66
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$242.91 M
|
$256.39 M
|
$220.18 M
|
$192.99 M
|
$144.54 M
|
$151.86 M
|
$0.00
|
| General & Administrative Expenses |
$71.67 M
|
$79.31 M
|
$74.11 M
|
$65.26 M
|
$57.47 M
|
$40.98 M
|
$24,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$22,000.00
|
| Selling, General & Administrative Expenses |
$71.67 M
|
$79.31 M
|
$74.11 M
|
$65.26 M
|
$57.47 M
|
$40.98 M
|
$2,000.00
|
| Other Expenses |
$13.25 M
|
-$1.75 M
|
-$2.93 M
|
-$1.14 M
|
-$268,000.00
|
-$21.21 M
|
$0.00
|
| Operating Expenses |
$327.83 M
|
$335.69 M
|
$294.28 M
|
$258.24 M
|
$202.01 M
|
$192.84 M
|
$2,000.00
|
| Cost And Expenses |
$327.83 M
|
$335.69 M
|
$294.28 M
|
$258.24 M
|
$202.01 M
|
$192.84 M
|
$2,000.00
|
| Interest Income |
$18.31 M
|
$4.57 M
|
$1.71 M
|
$9.16 M
|
$17.35 M
|
$5.79 M
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.36 M
|
$0.00
|
| Depreciation & Amortization |
$14.20 M
|
$14.30 M
|
$10.45 M
|
$11.54 M
|
$5.03 M
|
$1.50 M
|
$24,000.00
|
| EBITDA |
-$300.29 M |
-$321.24 M |
-$169.74 M |
-$250.81 M |
-$179.90 M |
-$206.76 M |
$22,000.00 |
| EBITDA Ratio |
-3160.98
|
-1380.45
|
-6.65
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-3449.86
|
-1380.45
|
-6.65
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$472,000.00
|
-$4.88 M
|
-$1.86 M
|
$8.02 M
|
$17.08 M
|
-$18.78 M
|
-$22,000.00
|
| Income Before Tax |
-$327.27 M
|
-$332.63 M
|
-$257.01 M
|
-$250.22 M
|
-$184.93 M
|
-$211.62 M
|
-$2,000.00
|
| Income Before Tax Ratio |
-3444.89
|
-1368.86
|
-6.68
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$2.82 M
|
-$12.17 M
|
-$16.75 M
|
-$331,000.00
|
-$117,000.00
|
-$24,000.00
|
| Net Income |
-$327.27 M
|
-$329.82 M
|
-$244.84 M
|
-$233.47 M
|
-$184.59 M
|
-$211.51 M
|
-$2,000.00
|
| Net Income Ratio |
-3444.89
|
-1357.26
|
-6.36
|
0
|
0
|
0
|
0
|
| EPS |
-2.09 |
-2.3 |
-1.8 |
-1.94 |
-1.83 |
-7.31 |
0 |
| EPS Diluted |
-2.09 |
-2.3 |
-1.8 |
-1.94 |
-1.83 |
-7.31 |
0 |
| Weighted Average Shares Out |
$156.93 M
|
$143.15 M
|
$135.82 M
|
$120.37 M
|
$101.06 M
|
$28.95 M
|
$117.93 M
|
| Weighted Average Shares Out Diluted |
$156.93 M
|
$143.15 M
|
$135.82 M
|
$120.37 M
|
$101.06 M
|
$28.95 M
|
$117.93 M
|
| Link |
|
|
|
|
|
|
|
